Precision Biologics is advancing its clinical trials with its leading monoclonal antibody candidate - referred to as Ensituximab or NEO-102 - which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers.

Precision has contracted Cytovance Biologics as its CMO to provide technology transfer and additional cGMP manufacturing services of NEO-102 in support of its ongoing Phase 2 clinical trials.

“With this agreement, Precision Biologics is strengthening its longstanding and growing relationship with the scientific professionals of Cytovance,” said Dr. Albine Martin, COO of Precision Biologics, Inc. “Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers.”

“Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics, Inc.

Head continued, “We are proud to be an established partner with Precision Biologics and support them in their expanded clinical trial program.”

New research indicates that cancer survivors carry greater financial burdens related to medical debt payments and bills compared with individuals without a cancer history, with the greatest hardships in younger survivors.

A team at Tokyo Medical and Dental University has revealed the molecule to cancer development, showing that its absence leads to dysregulation of the cell cycle, albeit with differing cancer-related outcomes.